Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA warns consumers about Que She

This article was originally published in The Tan Sheet

Executive Summary

FDA warns consumers to stop using the weight-loss capsules Que She and consult health care providers because the product contains undeclared active pharmaceutical ingredients that could endanger people with heart conditions. Undeclared ingredients include the Rx weight-loss ingredient sibutramine, which can increase the risk of heart attack and stroke, and the stimulant fenfluramine, which was removed from the U.S. market in 1997 after studies showed it damaged heart valves. The Rx beta blocker propranolol and the stimulant ephedrine also were found in the capsules and pose a risk to people with heart conditions, FDA said July 8. Principal Deputy Commissioner Josh Sharfstein said removing "spiked" supplements from the market is a priority (1"The Tan Sheet" Oct. 26, 2009)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS104288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel